This is a $93,736,520.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to The Emmes Company LLC for clinical trials and information management support services. The contract has a seven-year period of performance from June 1, 2021 to May 31, 2028. This is a re-competition of a previous contract held by Emmes. The contract supports NCI's Division of Cancer Treatment and Diagnosis and its Cancer Therapy Evaluation Program, including coordination of the NCI National...
The National Cancer Institute (NCI) awarded a 10-year, $151,756,070.00 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Theradex Systems, Inc. to provide broad-based, centralized, and fully integrated operational, administrative, regulatory, information technology, and logistical support services for multi-institutional cancer trials led by NCI-supported clinical trial organizations. This contract is a re-competition of previous IDIQ contracts and includes six task areas, with three of...
This is a $38,691,250.00 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Agile Decision Sciences, LLC, an Alaskan Native Corporation-owned small disadvantaged business. The contract is for clinical data management services in support of approximately 500 open clinical trials conducted by NCI's Center for Cancer Research (CCR). The original contract opportunity was a competitive 8(a) set-aside...
This is a $111,883,041.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI) to Technical Resources International, Inc. (TRI) for drug development support services for the Cancer Therapy Evaluation Program (CTEP). The contract is not set aside. TRI, a minority-owned, woman-owned, and Hispanic American-owned small business, will provide a wide range of drug development support activities to assist NCI in fulfilling its regulatory responsibilities to the FDA. This includes...
The National Cancer Institute (NCI) awarded a $55,311,391.18 cost-plus-fixed-fee contract to Technical Resources International, Inc. (TRI) for Drug Development Support for the Cancer Therapy Evaluation Program (CTEP). The contract, which runs through September 30, 2022, provides comprehensive clinical research support services to NCI, including clinical trials execution, regulatory support, research operations, and specialized scientific services. TRI, a minority-owned, woman-owned, and Hispanic...
This is a $115,518,487 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The contract provides clinical trials sponsor and regulatory management support services to the NCI, the Center for Cancer Research (CCR), and CCR investigators. The contract includes services such as compliance with U.S. and international regulations, regulatory support,...
This is a $5,727,440.77 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI) to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business. The contract is for Cancer Prevention Clinical Trials Auditing and Informatics Support services, with a period of performance through May 15, 2024. TRI is an experienced federal contractor, holding several significant Indefinite Delivery Vehicle (IDV) contracts with agencies...
This is a five-year, $30,206,398 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Asrc Federal Technology Solutions, LLC, an Alaskan Native Corporation-owned firm. The contract is for central support services for the NCI's Center for Cancer Research (CCR) clinical trials portfolio. Key requirements include a comprehensive quality assurance and quality control program, IT systems and programming support for databases and systems used in clinical research,...
This is a $87,762,620.22 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to The Emmes Company LLC, a for-profit limited liability company based in Rockville, Maryland. The contract is for providing direct organizational and data management support for specific clinical trials programs, as well as support for the NCI's Clinical Trials Evaluation Program (CTEP) staff in acquiring, reviewing, and analyzing data and information resulting from extramural clinical research....
This federal contract award, valued at $27,664,149.00, was made by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the Childhood Cancer Data Initiative: Clinical Trial Specimen Molecular Characterization (CTSMC) Program, which involves delivering a comprehensive range of biomedical research and facilities support services to the NCI. This includes services such as facilities operations and maintenance, research and...
This is a $36,506,288.06 cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI) to Theradex Systems, Inc. for clinical trials monitoring services. The contract has a performance period from May 1, 2017 to April 30, 2022.
The contract supports NCI's Experimental Therapeutics Clinical Trials Network (ETCTN), National Clinical Trials Network (NCTN), and National Community Oncology Research Program (NCORP), as well as the NCI COVID-19 in Cancer Patients Study (NCCAPS) and the Cancer Moonshot Biobank Project. Key services include data management, quality assurance, clinical trial monitoring and auditing, and integration of clinical and biomarker data. There was no set-aside designation for this contract.